Skip to content

Impairment Charges at other companies

Revvity logo
RevvityRVTY
$1.2M-79.0%
Maravai LifeSciences Holdings, Inc. logo
Maravai LifeSciences Holdings, Inc.MRVI
$605K-95.1%
Agilent Technologies logo
Agilent TechnologiesA
$15M
10x Genomics, Inc. logo
10x Genomics, Inc.TXG
$313.25K
Azenta logo
AzentaAZTA
$149.08M
Danaher logo
DanaherDHR
$0-100%

Segments

By segment

See full
Reportable Segment$0-100%

Other financials

Income statement

See full
Revenue$37.2M+0.1%
Gross profit$12.8M+1,037%
Operating income-$8.4M+98.1%
Net income-$8.3M+98.1%
EPS (diluted)-$0.03+97.9%

Balance sheet

See full
Cash & equivalents$57.9M-4.7%
Total debt$59.3M+12.1%
Total equity$2.4M-97.4%
Total assets$782.4M-9.1%

Cash flow

See full
Operating cash flow-$44.7M-1.4%
CapEx$3.0M+119%
Free cash flow-$47.7M-5.0%

Valuation

See full
Market cap$496.96M+30.4%
Enterprise value$498.38M+33.5%
P/S3.1×+0.6×

Profitability

See full
Gross margin37.5%+21.3pp
Operating margin-83.3%-38.2pp
Net margin-80.3%-36.1pp
FCF margin-72.6%-20.0pp

Returns & leverage

See full
Return on equity-273.6%+314pp
Debt / equity25.1×+24.5×
Current ratio5.7×-1.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:GoodwillAndIntangibleAssetImpairment.

The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacific Biosciences of California's impairment charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacific Biosciences of California's impairment charges?
Pacific Biosciences of California (PACB) reported impairment charges of $0 in Q1 2026.
How has Pacific Biosciences of California's impairment charges changed year-over-year?
Pacific Biosciences of California's impairment charges decreased by 100.0% year-over-year, from $15M to $0.
What does impairment charges mean?
Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.